Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients

Table 2

Patient clinicopathological characteristics according to the Eg5 score.

Characteristic	n	Eg5 expression, n (%)		Pearson χ^2
		Negative	Positive
Total	156	51 (32.69)	105 (67.31)
Gender				0.132	0.717
Male	119	38 (31.93)	81 (68.07)
Female	37	13 (35.14)	24 (64.86)
Age				1.867	0.172
<60	109	39 (35.78)	70 (64.22)
≥60	45	11 (24.44)	34 (75.56)
Unknown	2
Differentiation				2.092	0.351
Well	12	6 (50.00)	6 (50.00)
Middle	113	34 (30.09)	79 (69.91)
Poor	31	11 (35.48)	20 (64.52)
Liver cirrhosis				4.298	0.038
Yes	99	26 (26.26)	73 (73.74)
No	46	20 (43.48)	26 (56.52)
Unknown	11
Gross classification				0.093	0.760
Solitary	139	46 (33.09)	93 (66.91)
Multiple	17	5 (29.41)	12 (70.59)
Hepatitis B viral infection				1.115	0.291
Yes	12	2 (16.67)	10 (83.33)
No	128	39 (30.47)	89 (69.53)
Unknown	16
Vascular invasion				2.121	0.145
Yes	68	18 (26.47)	50 (73.53)
No	88	33 (37.50)	55 (62.50)
Tumor diameter				1.974	0.160
<5 cm	93	35 (37.63)	58 (62.37)
≥5 cm	60	16 (26.67)	44 (73.33)
Unknown	3
TNM stage				9.710	0.008
I	79	30 (37.97)	49 (62.03)
II	66	21 (31.82)	45 (68.18)
III	11	0 (0.00)	11 (100.00)
α-Fetoprotein (ng/ml)				0.959	0.327
<20	51	13 (25.49)	38 (74.51)
≥20	68	23 (33.82)	45 (66.18)
Unknown	37

.